Precision BioSciences Net Worth
Precision BioSciences Net Worth Breakdown | DTIL |
Precision BioSciences Net Worth Analysis
Precision BioSciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Precision BioSciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Precision BioSciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Precision BioSciences' net worth analysis. One common approach is to calculate Precision BioSciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Precision BioSciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Precision BioSciences' net worth. This approach calculates the present value of Precision BioSciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Precision BioSciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Precision BioSciences' net worth. This involves comparing Precision BioSciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Precision BioSciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Precision BioSciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Precision BioSciences' net worth research are outlined below:
| Precision BioSciences had very high historical volatility over the last 90 days | |
| Precision BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 48.73 M. Net Loss for the year was (61.32 M) with profit before overhead, payroll, taxes, and interest of 75.1 M. | |
| Precision BioSciences currently holds about 184.14 M in cash with (84.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Precision BioSciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 |
Precision BioSciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Precision BioSciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Precision BioSciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Precision BioSciences Target Price Consensus
Precision target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Precision BioSciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Precision analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Precision stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Precision BioSciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPrecision BioSciences Target Price Projection
Precision BioSciences' current and average target prices are 5.45 and 33.60, respectively. The current price of Precision BioSciences is the price at which Precision BioSciences is currently trading. On the other hand, Precision BioSciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Precision BioSciences Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Precision BioSciences Target Price
Know Precision BioSciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Precision BioSciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Precision BioSciences backward and forwards among themselves. Precision BioSciences' institutional investor refers to the entity that pools money to purchase Precision BioSciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-12-31 | 55.1 K | Squarepoint Ops Llc | 2024-12-31 | 46.9 K | Royal Bank Of Canada | 2024-12-31 | 42.3 K | Jane Street Group Llc | 2024-12-31 | 38.4 K | Northern Trust Corp | 2024-12-31 | 37.1 K | Bank Of America Corp | 2024-12-31 | 28.5 K | Susquehanna International Group, Llp | 2024-12-31 | 27.5 K | State Street Corp | 2024-12-31 | 22 K | Tejara Capital Ltd | 2024-12-31 | 21.2 K | Tang Capital Management Llc | 2024-12-31 | 673.3 K | Aquilo Capital Management, Llc | 2024-12-31 | 536.4 K |
Follow Precision BioSciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.12 M.Market Cap |
|
Project Precision BioSciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (3.74) | (3.55) |
When accessing Precision BioSciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Precision BioSciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Precision BioSciences' profitability and make more informed investment decisions.
Evaluate Precision BioSciences' management efficiency
Precision BioSciences has return on total asset (ROA) of (0.0638) % which means that it has lost $0.0638 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2444 %, meaning that it created $0.2444 on every $100 dollars invested by stockholders. Precision BioSciences' management efficiency ratios could be used to measure how well Precision BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.48. At this time, Precision BioSciences' Non Current Assets Total are quite stable compared to the past year. Other Current Assets is expected to rise to about 8.5 M this year, although the value of Net Tangible Assets will most likely fall to about 52.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.42 | 4.20 | |
| Tangible Book Value Per Share | 4.33 | 4.11 | |
| Enterprise Value Over EBITDA | 1.22 | 1.28 | |
| Price Book Value Ratio | 2.01 | 2.11 | |
| Enterprise Value Multiple | 1.22 | 1.28 | |
| Price Fair Value | 2.01 | 2.11 | |
| Enterprise Value | -49.8 M | -47.4 M |
The operational strategies employed by Precision BioSciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 0.1802 | Revenue | Quarterly Revenue Growth (0.96) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Precision BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Precision BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Precision BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Precision BioSciences Corporate Filings
| 18th of March 2025 Other Reports | ViewVerify | |
8K | 7th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify |
Precision BioSciences Earnings Estimation Breakdown
The calculation of Precision BioSciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Precision BioSciences is estimated to be 0.2575 with the future projection ranging from a low of 0.1225 to a high of 0.3925. Please be aware that this consensus of annual earnings estimates for Precision BioSciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.12 Lowest | Expected EPS | 0.39 Highest |
Precision BioSciences Earnings Projection Consensus
Suppose the current estimates of Precision BioSciences' value are higher than the current market price of the Precision BioSciences stock. In this case, investors may conclude that Precision BioSciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Precision BioSciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 5 | 34.4% | -2.25 | 0.2575 | 0.4 |
Precision BioSciences Earnings per Share Projection vs Actual
Actual Earning per Share of Precision BioSciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Precision BioSciences predict the company's earnings will be in the future. The higher the earnings per share of Precision BioSciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Precision BioSciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Precision BioSciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Precision BioSciences should always be considered in relation to other companies to make a more educated investment decision.Precision Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Precision BioSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -1.92 | -2.25 | -0.33 | 17 | ||
2024-08-01 | 2024-06-30 | -1.5 | 4.67 | 6.17 | 411 | ||
2024-05-13 | 2024-03-31 | -1.91 | -0.35 | 1.56 | 81 | ||
2024-03-27 | 2023-12-31 | -2.05 | -4.06 | -2.01 | 98 | ||
2023-11-07 | 2023-09-30 | -0.16 | -0.07 | 0.09 | 56 | ||
2023-08-04 | 2023-06-30 | -0.24 | -0.1 | 0.14 | 58 | ||
2023-05-09 | 2023-03-31 | -0.23 | -0.23 | 0.0 | 0 | ||
2023-03-09 | 2022-12-31 | -0.21 | -0.26 | -0.05 | 23 | ||
2022-11-08 | 2022-09-30 | -0.26 | -0.22 | 0.04 | 15 | ||
2022-08-08 | 2022-06-30 | -0.41 | -0.46 | -0.05 | 12 | ||
2022-05-09 | 2022-03-31 | -0.54 | -0.46 | 0.08 | 14 | ||
2022-03-15 | 2021-12-31 | -0.47 | -0.52 | -0.05 | 10 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.19 | 0.4 | 67 | ||
2021-08-12 | 2021-06-30 | -0.44 | 0.36 | 0.8 | 181 | ||
2021-05-13 | 2021-03-31 | -0.5 | -0.33 | 0.17 | 34 | ||
2021-03-18 | 2020-12-31 | -0.11 | -0.44 | -0.33 | 300 | ||
2020-11-10 | 2020-09-30 | -0.66 | -0.5 | 0.16 | 24 | ||
2020-08-13 | 2020-06-30 | -0.59 | -0.63 | -0.04 | 6 | ||
2020-05-15 | 2020-03-31 | -0.52 | -0.52 | 0.0 | 0 | ||
2020-03-10 | 2019-12-31 | -0.48 | -0.36 | 0.12 | 25 | ||
2019-11-12 | 2019-09-30 | -0.5 | -0.41 | 0.09 | 18 | ||
2019-08-14 | 2019-06-30 | -0.47 | -0.39 | 0.08 | 17 | ||
2019-04-29 | 2019-03-31 | -0.39 | -1.99 | -1.6 | 410 | ||
null | null | null | null | null | 0 | ||
2018-10-19 | 2018-09-30 | 0 | -0.15 | -0.15 | 0 |
Precision BioSciences Corporate Management
| Maurissa Messier | Senior Communications | Profile | |
| Fayaz Khazi | Chief Systems | Profile | |
| Derek Jantz | Chief CoFounder | Profile | |
| Jefferson Smith | CoFounder Officer | Profile | |
| Cassie Gorsuch | Chief Officer | Profile | |
| Bruce Stevens | Vice Compliance | Profile | |
| John Kelly | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.